0%

est. 2Y upside i

HealthcareSeries A

Orchid is a reproductive technology startup that is capable of detecting rare genetic disorders. Orchid’s preconception system analyzes both partners’ genomes and assesses genetic predispositions to common diseases, including heart disease, stroke, schizophrenia, Alzheimer’s disease, breast cancer, and diabetes.

Rank

#2057

Sector

Biotech, HealthTech

Est. Liquidity

~5Y

Data Quality

Data: Low

Orchid is a high-risk, high-reward opportunity for a job candidate.

Last updated: July 20, 2026

Bull (15%)+400%

If Orchid achieves significant revenue traction from its whole-genome embryo screening and capitalizes on growing IVF market, valuation could rise substantially, but upside is capped at 400% per stage constraints. Requires successful commercialization and possible IPO window within 2 years.

Base (40%)0%

Uncertain outlook due to lack of revenue data and stale valuation. Orchid may need to raise additional capital, diluting equity, and growth may not materialize as expected.

Bear (45%)-100%

If Orchid fails to generate revenue or faces regulatory/ethical setbacks, the company could be worth less than total funding, common stock would be worthless. Preference stack absorbs any exit value.

Est. time to liquidity~5.0 years

Preference Stack Risk

high

Funding Intensity

0%

Total funding of $16.5M may represent a significant portion of the company's current valuation given the early stage, putting common stock at risk in a downside exit.

Dilution Risk

high

With likely need for additional capital within 24 months, employee equity could face substantial dilution.

Secondary Liquidity

none

No secondary market activity detected; liquidity likely only through exit event.

Other — 1 role

View all 1 open roles at Orchid →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Orchid's data — designed to show you've done your homework.

  • 1

    “What is the company's current cash runway and burn rate?”

  • 2

    “How does Orchid plan to scale revenue given the high capital intensity and regulatory complexity?”

  • 3

    “What is the expected timeline to an IPO or acquisition, and what milestones must be met?”

Community

Valuation Sentiment

Our model estimates 0% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.